Kirkland Advises Investor Consortium in Take-Private of Cellular Biomedicine

Kirkland & Ellis is advising an investor consortium led by Mr. Bizuo (Tony) Liu, the Chief Executive Officer of Cellular Biomedicine Group Inc. (NASDAQ: CBMG), certain other senior management members of Cellular Biomedicine, Hillhouse Bio Holdings, L.P. and TF Capital Ranok Ltd. and also included Dangdai International Group Co., Limited and Mission Right Limited in a proposed take private of Cellular Biomedicine for US$19.50 per share.

Cellular Biomedicine is a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases.

Read the company press release

The Kirkland team is being led by transactional partners Nicholas Norris, Daniel Dusek, David Feirstein and Xiaoxi Lin.